Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Rosetta Genomics has won a European patent covering the use of miR-34a in the preparation of pharmaceuticals used to treat p53-negative cancers.
Subscribe to our email newsletter
The patent covers a core element of Rosetta’s microRNA technology in the development of cancer therapeutics associated with p53-negative cancers.
Rosetta Genomics president and chief executive officer Kenneth Berlin said, "This patent is important as it protects key elements of our microRNA technology to develop treatments for a variety of cancers."
The issued patent is collectively owned with Yeda, the technology transfer company of the Weizmann Institute of Science.
The miR-34a is a direct transcriptional target of p53, which may mediate some of the biological effects of the tumor suppressor.